D
ESPITE advances in the understanding of tumor biology at the cellular and genetic level, there has been no significant recent increase in the survival period of patients with glioblastomas. Less than one-half of patients survive at 1 year, most die within 2 years, and the limitations of surgery and radiation therapy are well known. Since an important advantage of immunotherapy is its potential for high tumor specificity, it has been investigated in various forms to examine antitumor activity in patients with brain tumors. However, numerous trials using intravenous, intratumoral, and intrathecal immunotherapy have had limited or no success) 7~ ]"s Recently, new methods of adoptive immunotherapy have been successful in treating certain advanced cancers outside the central nervous system) ~176
In animal models and in patients, disseminated tumors in the lungs, peritoneum, liver, and other locations have been reduced or eliminated by the administration of activated lymphocytes and cytokines. Nonetheless, immune responses against brain tumors remain elusive. Animal brain tumors are unresponsive to interleukin-2 and lymphokine-activated killer cells ~ and to tumor-infiltrating lymphocytes (TIL's) (SC Saris, unpublished data). Furthermore, in clinical Major histocompatibilitv antigen expression on brain tumols trials, many patients with stable or regressing tumors in extracranial sites have rapidly progressive metastatic disease in the b,ain2
One explanation for the apparent immune privilege of tumors in the brain is poor expression of major histocompatibility antigens. A cell-mediated immune response against tumors can only occur in the presence of appropriate major histocompatibility comp]ex antigens on the surface of tumor cells.~ T-helper cells recognize foreign antigens when they are presented in association with Class II major histocompatibility complex antigens, and cytotoxic T cells recognize targets carrying Class I antigen molecules on their cell surface. In vivo studies by Weber, el al., ee have documented the importance of major histocompatibility complex expression for recognition of tumors by therapeutic TIL's. They conclude that proper major histocompatibility complex antigen expression is probably necessary, but not sufficient, for an effective immune response to a given tumor target. ~e
Little is known about expression of major hislocompatibility complex antigens by animal brain tumors. For this reason, we analyzed expression of these cellsurface determinants on three murine gliomas and examined their potential for up-regulation after exposure to one of five cytokines or eytokine combinations in vilro. If this expression was found to be similar to that observed in patients with gliomas, an animal model would then be available in which to conduct correlative in vivo studies to determine whether major histocompatibility complex antigen up-regulation can bring about increased effectiveness of immunotherapy against brain tumors.
Materials and Methods

Animals and Tumor CelLv
Twelve-week-old female C57BL/6 mice were used in all experiments.* Cryopreserved tumor fragments of the murine glioma 26 (GL26), glioma 261 (GL261), and ependymoblastoma A (EpA) cell lines were obtained;) these are primary mouse brain-tumor cells that were induced in the brains of C57BL/6 mice after intracerebral implantation of methylcholanthrene pellets. ~ Although these tumors do not express glial fibrillary acidic protein positivity (unpublished observations), they grow well after intracerebral inoculation in mice, demonstrate a moderate degree of invasiveness and infiltration, and result in death of the animal from mass effect in approximately 3 weeks. For these experiments, the tumors were grown in the flanks of C57BL/ 6 mice and maintained by serial subcutaneous transplantation approximately once every 3 weeks. * C57BL/6 mice supplied by Small Animal Section, National Institutes of Health, Bethesda, MaD'land.
"~ Cryopreserved tumor fragments supplied by the Division of Cancer Treatment Repositou. Frederick, Maryland.
l'ri't~aratilm te/ Mono/ayer ('ultures
After the mice were sacrificed by cervical dislocation, the flank tumors were removed and minced using sterile technique. This slurry was stirred in a flask for 2 hours at room temperature in 28 cc of Hanks' balanced salt solution and 5 cc each of deoxyribonuclease, hyaluronidase, and collagenase. The resultant single-cell suspension was filtered through a nylon mesh and counted by trypan blue dye exclusion. One million viable tumor cells were placed in flasks containing 15 ml of complete medium consisting of Dulbecco's minimum essential medium with 10% fetal calf serum, 0.05 mM 2-mercaptoethanol, 0.1 mM nonessential amino acids, 0.1 mM sodium pyruvate, 300 mg/ml L-glutamine, 100 U/ ml penicillin, 100 mg/ml streptomycin, and 50 mg/ml gentamicin sulfate. Cells were incubated at 37~ in an atmosphere of 5% CO2. Cells at confluence were subcultured and used in either the second or third passage for experiments.
E~7)erimenla/ Design
One million tumor cells were placed in each of six flasks containing complete medium. No cytokines were added to the first flask. The following cytokines were added to the five remaining flasks: tumor necrosis factor alpha (100 U/ml); gamma interferon (I00 U/ml); alpha interferon (1000 U/ml); interleukin-2 (1000 U/ml); and gamma interferon (100 U/ml) plus tumor necrosis factor alpha (100 U/ml).:l: After 48 hours, cells were harvested using standard trypsinization techniques. Each experiment was repeated at least twice.
To determine the duration of up-regulation after cytokine priming, five flasks were prepared with one million GL261 cells. Each was incubated with gamma interferon plus tumor necrosis factor alpha (100 U/ml each). After 48 hours, the cells in one flask were harvested and analyzed for Class I and Class II antigen expression. The media in the other five flasks were removed and replaced with complete media. The cells in these flasks were harvested at 2, 4, 5, 6, and 7 days and analyzed for Class I and Class II antigen expression. This experiment was repeated twice.
kTuorescence-Activaled Cell Sorler Analysis
Tumor-cell surface-antigen phenotyping was performed with a fluorescence cell sorter.{} Briefly, 1 • 10 ~' cells were aliquoted per tube and incubated for 30 minutes at 4~ with 10 to 15 ul of the appropriate primary antibody. These cells were then incubated with 10 s~l fiuorescein isothiocyanate-labeled goat antibodies ~e The recombinant cytokines were gifts of the following corporations: interleukin-2, Cetus, Emeryville, California: alpha interferon, Hoffman-LaRoche, Nutley, New Jersey: murine gamma interferon, Genzyme, Boston, Massachusetts: and tumor necrosis factor alpha, Cellular Products, Inc., Buffalo, New York.
w FACScan fluorescence cell sorter manufactured by Becton Dickinson, Mountain View, California. "f Percentage of cells that constitutively express Class I antigens at baseline and after cylokine treatment.
Mean channel fluorescence before cytokine priming (baseline) and after modulation with cytokines. The cytokine effect was calculated as the mean channel fluorescence after cytokine modulation divided by the mean channel fluorescence before cytokine modulation. 
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* All numbers were rounded off to the nearest integer and are expressed as means • standard deviations. EpA = murine ependymobias?area A cell line: GL261 = routine glioma 261 cell line; GL26 = murine glioma 26 cell line: a-IFN = alpha interferon; ~,-IFN = gamma interferon: TNF-a = tumor necrosis factor alpha; IL-2 = interleukin-2.
t Percentage of cells that constitutively express Class I antigens at baseline and after cylokine treatment.
Mean channel fluorescence before cytokine priming (baseline) and after modulation with c~1okines. The cytokine effect was calculated as the mean channel fluorescence after cytokine modulation divided by the mean channel fluorescence before cytokine modulation.
to mouse immunoglobulin G (IgG) heavy and light chains and analyzed by flow cytometry. For each flask of experimental cells, four analyses were performed. In the first, no primary antibody was added in order to determine background fluorescence. In the second, an isotype-specific antibody against antigen la k was added as an irrelevant control to determine the amount of nonspecific staining. In the third, the antibody against Class I antigen was added. In the fourth, the antibody against Class II antigen was added.
Antibodies
The antibody against Class I antigens K b and D b was designated 28-8-6; the antibody against Class II antigen Iah was designated 25-9-17. Both were murine lgG2. I[ Isotype-specific irrelevant antibody was directed against Ia k.
Data Anah,sis
To determine the level of major histocompatibility complex expression, the flow cytometry profile of the I] Antibodies 28-8-6 and 25-9-17 kindly provided by Dr. David Sachs of the National Cancer Institute, Bethesda, Maryland. untreated cells was compared to that of unstained control cells. The percentage of cells to the fight of the curve for unstained control cells was considered positive for the determinant being examined. A fluorescence of 10 to 100 was considered a low degree of antigen expression, 100 to 200 was considered a medium deglee, and 200 to 300 was considered a high degree. 2s To quantify up-regulation of a particular antigen after treatment with cytokines, the mean channel fluorescence (MCF) of treated cells was divided by the MCF of the control cells. This ratio was called the "cytokine effect." A significant up-regulation was assigned if a greater than 50% increase in expression occurred in more than two-thirds of the experiments assessing the effect of a specific cytokine on a specific antigen.
Results
Constitutive Expression of Major Histocompatibi[io Complex Antigens
Expression of Class I and Class II antigens was similar among the three glioma lines we examined (Tables 1  and 2 ). The percentages (means _+ standard deviations) of untreated EpA, GL26, and GL261 cells that expressed the Class I antigen were 81% + 23%, 87% + 15%, and 77% + 26%, respectively ( Table 1 ). The percentages that expressed the Class It antigen were 0.6% _+ 0.2%, 0.0%, and 4.5% + 6.5%, respectively (Table 2) .
E{]bcts of Cytokines on Class 1 Antigen Expression
Tumor necrosis factor alpha and interleukin-2 had no effect on Class I antigen expression in any cell line, although in occasional experiments there was a minimal effect (Table 1 and Fig. 1 left) . Alpha interferon caused substantial up-regulation in all cell lines. In experiments where untreated cells did not express Class I antigens, alpha interferon induced expression in most of the cells. In one experiment with GL26 cells, 62% of untreated cells expressed Class I antigens; after treatment with alpha interferon, 96% of cells expressed this molecule. In cell lines that already expressed Class I antigen, incubation with alpha interferon doubled or tripled the MCF. In EpA, GL261, and GL26 cells, treatment with alpha interferon increased MCF from 20 + 10 to 52 + 34, 14 + 6 to 46 _+ 15, and 26 + 11 to 50 + 17, respectively. Gamma interferon induced a modest, but significant, mean increase of Class I antigen expression of 1.7 • 1.5 • and 2.1 • control values for the EpA, GL26, and GL261 cell lines, respectively. The addition of tumor necrosis factor alpha to gamma interferon augmented the up-regulating effect of gamma interferon on EpA cells.
Effects of Cytokines on Class H Antigen Expression
Tumor necrosis factor alpha, alpha interferon, and interleukin-2 had no effect on the expression of the Class II antigen determinant in any cell line (Table 2 and Fig. 1 right) . For EpA cells, gamma interferon caused the fluorescence intensity to increase to 1.9 x control. The addition of tumor necrosis factor alpha to gamma interferon increased this up-regulation to a mean of 4.6 • control. In numerous experiments, there was no Class II antigen expression in control cells, but treatment with tumor necrosis factor alpha plus gamma interferon augmented Class II antigen expression in up to 25% of cells. For GL26 cells, the anti-Class II antigen fluorescence intensity of cells treated with gamma interferon or tumor necrosis factor alpha plus gamma interferon increased 14-to 17-fold. In two of three experiments, there was no pretreatment expression of the Class I1 antigen; however, after treatment with gamma interferon, 73% of cells expressed this determinant to a low degree (MCF 38 to 58). The addition of tumor necrosis factor alpha to gamma interferon caused 85% of the cells to express major histocompatibility complex Class It antigen, suggesting a minimal additive effect. The results for GL261 cells were similar to those for the GL26 cells, although not as extreme. 
Duration q/" Ell'eels
After 48 hours of GL261 cell treatment with tumor necrosis factor alpha plus gamma interferon, the MCF of Class I antigen increased to 62. After the cytokines had been removed, this MCF continued to increase to 100 at 4 days, but had diminished to 75 at 7 days (Fig.  2 lr After 48 hours of treatment, the MCF of Class II antigen increased from less than 5 to 56. After cytokine removal, this decreased rapidly to an MCF of 20 at 4 days and returned to baseline at 6 days (Fig. 2  right) . This experiment was repeated twice with similar results (data not presented).
Discussion
Terminology
The majority of cells in the body have antigens on their surfaces that are unique to each person. These are called "major histocompatibility antigens" and were discovered when research was conducted to determine why the immune system of one individual will recognize and attempt to destroy tissue transplanted from another individual. The two main groups of major histocompatibility antigens are the Class I and Class 1I antigens. It has been discovered recently that the recognition and destruction of tumor cells by the immune system require expression of these antigens on their surfaces? 3 Additional work has determined that, when tumor cells do not have these antigens on their cell membranes, one can "up-regulate" expression with naturally occurring proteins (cytokines) such as gamma interferon, alpha interferon, and tumor necrosis factor alpha? ~ The objective of this study was to define the normal (or constitutive) expression of these antigens on the surface of murine glioma cells and to determine if this expression could be increased with cytokines.
Major Histocompatibility Antigen Expression on Glioma Cells
We observed that the majority of mouse glioma cells expressed low levels of major histocompatibility complex Class I antigens and no detectable Class II antigens. We could find no reports on major histocompatibility complex expression in rat, mouse, or other animal brain tumors with which to compare our findings. Piguet, et al, J2 established 10 human malignant glioma cell lines in vizro and found that all strongly expressed human leukocyte antigen (HLA)-A, HLA-B, and HLA-C (Class I), but only three were HLA-DR (Class II)-positive. In another study by Piguet, et al., ~3 nine of 22 established human glioma cell lines were HLA-DR-positive. Saito, eta/., t7 performed immunohistochemical analyses on tissues from 14 patients with malignant gliomas: all had intense staining for b-2 microglobulin (Class I); six of 14 specimens were positive for HLA-DR, four were weakly positive, and four were negative. Therefore, our findings in mice correspond with those in humans. Class I antigen expression is usually present, while Class II antigen expression is weak or absent.
Eft'co! oJ" Gamma lnterfet~m
In our experiments, gamma interferon had an upregulating effect that was modest on Class I antigens and profound on Class II antigens. We could find no previous reports on the modulating effect of gamma interferon on rodent brain tumors, although numerous investigators have studied the effect of this cytokine on normal brain cells both in vitro and in vivo. Wong, et al., > noted that there were no detectable Class I or II antigen determinants on the aslrocytes of newborn mice; however, after incubation with gamma interferon in vitro, all cells expressed a moderate amount of Class I antigen and 10% of cells expressed low levels of Class I1 antigen. The findings of Fierz, et al., 4 disagree with regard to Class II antigen modulation. They prepared astrocytes from the brains of Lewis rats and demonstrated la antigen expression (Class If) after incubation with 10 U/ml of gamma interferon. Additionally, they demonstrated that only after this modulating effect appeared could these astrocytes present antigen to activated lymphocytes. Pulver, et al., ~4 also demonstrated an up-regulating effect on la antigens when human fetal Major histocompatibiliLv antigen expression on brain lumors astrocytes were treated with ganqma intertL'ron. Piguet, el al., ~: treated I0 human glioma cell lines with gamma interferon and observed that Class 1 antigen expression (already present in all cell lines) was enhanced in seven and Class II antigen expression was induced in lhree. Thus, our observations are similar to the results of previous investigations of normal astrocytes and human gliomas except that lhe induction of Class II antigens in the three mouse gliomas was more consistent and extensive.
E{]i,ct o/ Tumor Necrosis l:aclor .llpha
The addition of tumor necrosis factor alpha to gamma interferon did not add significantly to the upregulating effect on Class I antigen, and only in one of three glioma lines (EpA) did it add substantially to the up-regulating effect of Class It antigen. We studied the effects of these two cytokines together because of their well-known synergy in the lysis of tumor cells. Fransen, eta[., ~ observed that tumor necrosis factor alpha plus gamma interferon is far more effective in destroying human breast, cervix, and colon carcinomas in vitro than tumor necrosis factor alpha alone. This was a direct effect rather than mediated by lymphoid effectots, and the modulation of major histocompatibility complex antigens was not studied. Weber and Rosenberg :3 investigated the modulating effect of these cytokines on mouse sarcomas of varying immunogenicity. Their findings concur with ours in regard to Class I antigens, but they observed no induction of Class II antigens with gamma interferon alone or with tumor necrosis factor alpha plus gamma interferon combined. We could find no reports on the effects of tumor necrosis factor alpha plus gamma interferon on mouse or human brain tumors in rive or in vitro.
Eff2,cl qf Alpha lnlerferon and Interleukin-2
In our glioma cell lines, most cells constitutively expressed Class I antigens, and alpha interferon substantially increased this expression. In contrast, there was no baseline expression of Class I1 antigens, and alpha interferon did not cause its induction. We could find no previous reports of the effect of alpha interferon on animal brain tumors, but these findings generally agree with studies of other normal and neoplastic tissues. Wens, el al.,'-4 treated the astrocytes of 2-day-old CBA mice with 200 U/ml of interferon-alpha/beta; there was induction of Class I antigen expression in 50% of cells, whereas there was no induction of Class It antigen expression. They suggested that the modulating effect of gamma interferon was 200-fold greater than alpha interferon in induction of Class I antigen. Similarly, Piguet, el al., ~2 incubated six human glioma cell lines with 5000 U/ml of alpha interferon for 4 days. There was increased expression of antigens HLA-A, HLA-B, and HLA-C in three of the six cell lines, but no effect on HLA-DR. Weber and Rosenberg > treated four mouse sarcoma lines with 1000 U/ml and observed a small, bul significant, increase of Class I antigen expression and no effect on Class II antigen expression. Since alpha interferon administered with interleukin-2 causes a synergistic effect in the regression of murine tumors outside the central nervous system, 2> we treated brain-tumor cells v~ith interleukin-2 and measured the effect on Class I and Class II antigen expression. lnterleukin-2 had no effect on either.
Biologica/ Rek, vance
The results of our study demonstrate a variable and often dramatic effect of different cytokines on major histocompatibility complex antigen expression by gliomas in vitro. A similar modulating effect in vivo requires that the cytokine be delivered to the tumor. Chemical characteristics that favor such penetration are a small molecule size, lipophilicity, low molecular binding to serum proteins, and carrier-mediated transport. The cytokines of interest (alpha interferon, gamma interferon, and tumor necrosis factor alpha) are relatively large proteins, and we are not aware of studies investigating their delivery, into brain tumors. Penetration of proteins into the cerebrospinal fluid (CSF) may reflect penetration into the brain, and Collins observed that only 1% of plasma alpha interferon (19,000 daltons) penetrated into the CSF of normal rhesus monkeys. The delivery, of interleukin-2 (15,000 daltons) was examined in patients receiving treatment for extracranial cancer. '~ At 4 hours, interleukin-2 levels began to rise in the CSF to as high as 9 U/ml and remained so until the end of therapy, at which time the level decreased over about 8 hours until it was undetectable. These reports suggest that the delivery of cytokines into normal brain is low or negligible. Although the permeability of brain-tumor vessels is increased compared to normal blood vessels, it is unclear whether this would increase cytokine delivery to levels necessary to affect major histocompatibility complex antigen expression.
If adequate cytokine delivery, to brain-tumor cells occurred, it is unclear if this would cause modulation of major histocompatibility complex antigen expression in the milieu of the brain and, if so, if it would alter clinical responses to immunotherapy. Weber and Rosenberg 2~ studied the effect of cytokines on pulmonary metastases in silu in C57BL/6 mice. In one study, immunohistochemical analysis demonstrated that the modulating effects observed in vilro were similar to those that could be demonstrated in rive. In a second study, Weber, et al., 22 showed no efficacy when interleukin-2 and tumor-infiltrating lymphocytes were used to treat pulmonary metastases that expressed low levels of Class I antigens. However, when these metastases were transfected with a gene encoding for Class I antigens, the pulmonary metastases were reduced or eliminated with TIL's and interleukin-2. These data suggest that major histocompatibility complex antigen expression and modulation observed in vitro also occur in rive, and that expression of major histocompatibility complex antigens may be a necessary, but not sufficient. condition for mounting an effective immune response against an in silzt tumor.
Time Coltr, s'e ~( L'p-Regulali~m
The kinetic data on the duration of major histocompatibility complex antigen up-regulation i~ vitro were surprising in that Class I antigen expression rose rapidly. then continued to rise for 3 days after the cytokine was removed. Weber and Rosenberg ~ studied the kinetics of major histocompatibility complex antigen induction in subcutaneous mouse sarcomas after parenteral treatment with alpha interferon. They also observed that the up-regulation of Class I antigen peaked 2 days after the end of treatment, then decayed to baseline over 4 to 7 days. Class II antigens also rose rapidly during treatment, but then rapidly decayed to baseline levels within 4 days. Although in vivo studies are necessary, these results suggest that frequent injections of modulating cytokines would be necessary to maintain increased Class ]I antigen expression. Less frequent treatments would be necessary for maintenance of increased Class I antigen expression.
Future Research
These findings provide an animal model for the in vivo study of brain-tumor major histocompatibility complex antigen expression and its potential relevance to the treatment of patients with brain tumors. The mouse brain tumors that we studied are similar to humans in regard to Class I and It antigen expression and respond similarly to cytokine treatment. These tumor cells are easily injected into the brains of C57BL/6 mice and result in death of the animal in approximately 3 weeks from an enlarging intracerebral mass. Future investigations using this system should shed light on the effect of cytokines on the lysis of modulated tumor cells by activated lymphocytes in vitro, their effect on brain-tumor major histocompatibility complex antigen expression in sire, and the effect of major histocompatibility complex antigen up-regulation (if present) on the effectiveness of immunotherapy against brain tumors in viw~.
